BioNTech (NASDAQ:BNTX) Coverage Initiated by Analysts at Berenberg Bank

Berenberg Bank began coverage on shares of BioNTech (NASDAQ:BNTX) in a research report report published on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $130.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. TD Cowen decreased their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Canaccord Genuity Group restated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $138.79.

BioNTech Trading Up 4.5 %

NASDAQ:BNTX opened at $113.13 on Tuesday. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $113.60 and a 200-day simple moving average of $97.70. The company has a market capitalization of $27.12 billion, a PE ratio of -53.87 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the firm posted $0.73 EPS. On average, equities research analysts expect that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC lifted its stake in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC acquired a new position in BioNTech during the third quarter valued at approximately $59,485,000. Candriam S.C.A. grew its stake in BioNTech by 261.2% during the second quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the period. Point72 Asset Management L.P. grew its stake in BioNTech by 283.5% during the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares during the period. Finally, Braidwell LP acquired a new stake in shares of BioNTech in the third quarter worth $29,425,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.